Gossamer Bio Inc (NASDAQ:GOSS)’s traded shares stood at 0.69 million during the last session, with the company’s beta value hitting 1.91. At the close of trading, the stock’s price was $1.06, to imply a decrease of -4.50% or -$0.05 in intraday trading. The GOSS share’s 52-week high remains $1.60, putting it -50.94% down since that peak but still an impressive 52.83% since price per share fell to its 52-week low of $0.50. The company has a valuation of $240.20M, with an average of 1.05 million shares in intraday trading volume over the past 10 days and average of 1.45 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Gossamer Bio Inc (GOSS), translating to a mean rating of 1.25. Of 10 analyst(s) looking at the stock, 0 analyst(s) give GOSS a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.17.
Gossamer Bio Inc (NASDAQ:GOSS) trade information
After registering a -4.50% downside in the last session, Gossamer Bio Inc (GOSS) has traded red over the past five days. The 5-day price performance for the stock is 6.68%, and -4.50% over 30 days. With these gigs, the year-to-date price performance is 17.18%. Short interest in Gossamer Bio Inc (NASDAQ:GOSS) saw shorts transact 6.25 million shares and set a 5.53 days time to cover.
The extremes give us $2 and $5 for target low and target high price respectively. As such, GOSS has been trading -371.7% off suggested target high and -88.68% from its likely low.
Revenue forecast for the current quarter as set by 9 analysts is 7.02M. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 3.48M.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 11.99% for the past 5-year period. While 2025 is set for a 76.06% return in earnings, projections for the next 5 years are at 26.42% annually.
GOSS Dividends
Gossamer Bio Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Gossamer Bio Inc (NASDAQ:GOSS)’s Major holders
Gossamer Bio Inc insiders hold 3.29% of total outstanding shares, with institutional holders owning 78.28% of the shares at 80.95% float percentage. In total, 78.28% institutions holds shares in the company, led by NEA MANAGEMENT COMPANY, LLC. As of 2024-06-30, the company held over 18.09 million shares (or 8.0152% of shares), all amounting to roughly $16.3 million.
The next major institution holding the largest number of shares is ARTAL GROUP S.A. with 13.31 million shares, or about 5.8958% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $11.99 million.
We also have Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Gossamer Bio Inc (GOSS) shares. Going by data provided on Nov 30, 2024 , Fidelity Select Portfolios – Biotechnology holds roughly 7.91 shares. This is just over 3.49% of the total shares, with a market valuation of $8.39 million. Data from the same date shows that the other fund manager holds a little less at 7.84, or 3.46% of the shares, all valued at about 8.31 million.
